|
2024-05-30 |
2024-05-28 |
V
Vente
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
300 000
-14.7%
34,30
10 290 000 USD
|
300 000
-14.7%
|
34,30
|
10 290 000 USD
|
|
|
2023-08-30 |
2023-08-28 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
511 627
+inf%
19,35
9 899 982 USD
|
511 627
+inf%
|
19,35
|
9 899 982 USD
|
|
|
2023-03-02 |
2023-03-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
400
-0.0%
24,71
9 883 USD
|
400
-0.0%
|
24,71
|
9 883 USD
|
|
|
2023-03-02 |
2023-03-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
39 600
-1.9%
24,20
958 348 USD
|
39 600
-1.9%
|
24,20
|
958 348 USD
|
|
|
2023-03-01 |
2023-02-28 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
60
-0.0%
25,02
1 501 USD
|
60
-0.0%
|
25,02
|
1 501 USD
|
|
|
2023-02-02 |
2023-02-02 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
1 130
-0.1%
25,89
29 261 USD
|
1 130
-0.1%
|
25,89
|
29 261 USD
|
|
|
2023-02-02 |
2023-02-02 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
10 120
-0.5%
25,40
257 094 USD
|
10 120
-0.5%
|
25,40
|
257 094 USD
|
|
|
2023-02-02 |
2023-02-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
693
-0.0%
25,66
17 780 USD
|
693
-0.0%
|
25,66
|
17 780 USD
|
|
|
2023-02-02 |
2023-02-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
14 608
-0.7%
25,08
366 366 USD
|
14 608
-0.7%
|
25,08
|
366 366 USD
|
|
|
2023-02-02 |
2023-02-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
13 449
-0.6%
24,29
326 710 USD
|
13 449
-0.6%
|
24,29
|
326 710 USD
|
|
|
2023-01-24 |
2023-01-24 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
63
-0.0%
26,11
1 645 USD
|
63
-0.0%
|
26,11
|
1 645 USD
|
|
|
2023-01-24 |
2023-01-24 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
4 272
-0.2%
25,71
109 833 USD
|
4 272
-0.2%
|
25,71
|
109 833 USD
|
|
|
2023-01-24 |
2023-01-23 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
21 665
-0.9%
25,36
549 364 USD
|
21 665
-0.9%
|
25,36
|
549 364 USD
|
|
|
2023-01-23 |
2023-01-23 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
9 500
-0.3%
25,26
239 999 USD
|
9 500
-0.3%
|
25,26
|
239 999 USD
|
|
|
2023-01-04 |
2023-01-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
3 003
-0.1%
23,99
72 043 USD
|
3 003
-0.1%
|
23,99
|
72 043 USD
|
|
|
2023-01-04 |
2023-01-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
4 102
-0.2%
23,11
94 786 USD
|
4 102
-0.2%
|
23,11
|
94 786 USD
|
|
|
2023-01-04 |
2023-01-03 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
2 084
-0.1%
25,09
52 293 USD
|
2 084
-0.1%
|
25,09
|
52 293 USD
|
|
|
2023-01-04 |
2023-01-03 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
8 598
-0.4%
24,36
209 426 USD
|
8 598
-0.4%
|
24,36
|
209 426 USD
|
|
|
2023-01-04 |
2023-01-03 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
22 213
-1.0%
23,41
520 051 USD
|
22 213
-1.0%
|
23,41
|
520 051 USD
|
|
|
2022-12-22 |
2022-12-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
1 959
-0.1%
27,61
54 088 USD
|
1 959
-0.1%
|
27,61
|
54 088 USD
|
|
|
2022-12-22 |
2022-12-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
7 541
-0.2%
26,87
202 591 USD
|
7 541
-0.2%
|
26,87
|
202 591 USD
|
|
|
2022-12-20 |
2022-12-19 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
754
-0.0%
26,29
19 820 USD
|
754
-0.0%
|
26,29
|
19 820 USD
|
|
|
2022-12-20 |
2022-12-19 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
25 246
-1.0%
25,53
644 624 USD
|
25 246
-1.0%
|
25,53
|
644 624 USD
|
|
|
2022-12-07 |
2022-12-06 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
1 392
-0.1%
28,46
39 617 USD
|
1 392
-0.1%
|
28,46
|
39 617 USD
|
|
|
2022-12-07 |
2022-12-06 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
17 681
-0.8%
27,57
487 493 USD
|
17 681
-0.8%
|
27,57
|
487 493 USD
|
|
|
2022-12-07 |
2022-12-06 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
20 927
-1.0%
26,83
561 572 USD
|
20 927
-1.0%
|
26,83
|
561 572 USD
|
|
|
2022-11-22 |
2022-11-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
6 767
-0.2%
30,12
203 819 USD
|
6 767
-0.2%
|
30,12
|
203 819 USD
|
|
|
2022-11-22 |
2022-11-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
2 733
-0.1%
29,33
80 153 USD
|
2 733
-0.1%
|
29,33
|
80 153 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
1 150
-0.0%
32,38
37 241 USD
|
1 150
-0.0%
|
32,38
|
37 241 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
912
-0.0%
30,67
27 969 USD
|
912
-0.0%
|
30,67
|
27 969 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
6 773
-0.3%
30,15
204 196 USD
|
6 773
-0.3%
|
30,15
|
204 196 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
1 767
-0.1%
28,86
50 991 USD
|
1 767
-0.1%
|
28,86
|
50 991 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
4 333
-0.2%
27,45
118 937 USD
|
4 333
-0.2%
|
27,45
|
118 937 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
4 106
-0.2%
26,57
109 098 USD
|
4 106
-0.2%
|
26,57
|
109 098 USD
|
|
|
2022-11-18 |
2022-11-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
6 959
-0.3%
25,36
176 477 USD
|
6 959
-0.3%
|
25,36
|
176 477 USD
|
|
|
2022-11-02 |
2022-11-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
12 349
-0.6%
33,90
418 641 USD
|
12 349
-0.6%
|
33,90
|
418 641 USD
|
|
|
2022-11-02 |
2022-11-01 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
27 651
-1.2%
33,34
921 746 USD
|
27 651
-1.2%
|
33,34
|
921 746 USD
|
|
|
2022-10-24 |
2022-10-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
5 928
-0.2%
30,58
181 255 USD
|
5 928
-0.2%
|
30,58
|
181 255 USD
|
|
|
2022-10-24 |
2022-10-21 |
VP
Vente planifiée
|
Kayyem Jon Faiz
Administrateur non-exécutif
|
3 572
-0.1%
29,39
104 977 USD
|
3 572
-0.1%
|
29,39
|
104 977 USD
|
|
|
2022-10-18 |
2022-10-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
121
-0.0%
31,51
3 812 USD
|
121
-0.0%
|
31,51
|
3 812 USD
|
|
|
2022-10-18 |
2022-10-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
2 892
-0.1%
30,81
89 090 USD
|
2 892
-0.1%
|
30,81
|
89 090 USD
|
|
|
2022-10-18 |
2022-10-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
14 006
-0.5%
29,92
419 123 USD
|
14 006
-0.5%
|
29,92
|
419 123 USD
|
|
|
2022-10-18 |
2022-10-17 |
VP
Vente planifiée
|
Lappe Mark
Chief Executive Officer
Administrateur exécutif
|
8 981
-0.3%
28,66
257 419 USD
|
8 981
-0.3%
|
28,66
|
257 419 USD
|
|
|
2022-10-12 |
2022-10-07 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
333 333
+inf%
30,00
9 999 957 USD
|
333 333
+inf%
|
30,00
|
9 999 957 USD
|
|
|
2022-10-12 |
2022-10-07 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
1 000 000
+70.1%
30,00
29 999 900 USD
|
1 000 000
+70.1%
|
30,00
|
29 999 900 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
100
-0.0%
30,52
3 052 USD
|
100
-0.0%
|
30,52
|
3 052 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
10 893
-0.5%
29,68
323 302 USD
|
10 893
-0.5%
|
29,68
|
323 302 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
5 954
-0.3%
28,97
172 495 USD
|
5 954
-0.3%
|
28,97
|
172 495 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
4 262
-0.2%
27,76
118 299 USD
|
4 262
-0.2%
|
27,76
|
118 299 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
11 136
-0.5%
26,78
298 182 USD
|
11 136
-0.5%
|
26,78
|
298 182 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
6 207
-0.3%
26,06
161 763 USD
|
6 207
-0.3%
|
26,06
|
161 763 USD
|
|
|
2022-10-05 |
2022-10-04 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
1 448
-0.1%
24,67
35 720 USD
|
1 448
-0.1%
|
24,67
|
35 720 USD
|
|
|
2022-09-07 |
2022-09-06 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
2 493
-0.1%
15,66
39 032 USD
|
2 493
-0.1%
|
15,66
|
39 032 USD
|
|
|
2022-09-07 |
2022-09-06 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
37 507
-1.5%
14,86
557 241 USD
|
37 507
-1.5%
|
14,86
|
557 241 USD
|
|
|
2022-08-04 |
2022-08-03 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
15 500
-0.6%
18,47
286 209 USD
|
15 500
-0.6%
|
18,47
|
286 209 USD
|
|
|
2022-08-04 |
2022-08-02 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
24 500
-1.0%
17,70
433 626 USD
|
24 500
-1.0%
|
17,70
|
433 626 USD
|
|
|
2022-07-08 |
2022-07-07 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
40 000
-1.6%
17,17
686 800 USD
|
40 000
-1.6%
|
17,17
|
686 800 USD
|
|
|
2022-04-07 |
2022-04-05 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Dirigeant
|
400
-0.0%
25,04
10 016 USD
|
400
-0.0%
|
25,04
|
10 016 USD
|
|
|
2021-03-24 |
2021-03-24 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Administrateur exécutif
|
17 000
-0.7%
19,02
323 340 USD
|
17 000
-0.7%
|
19,02
|
323 340 USD
|
|
|
2021-02-18 |
2021-02-17 |
VP
Vente planifiée
|
Wagner Klaus W.
Chief Medical Officer
Dirigeant
|
19 559
-8.3%
25,29
494 647 USD
|
19 559
-8.3%
|
25,29
|
494 647 USD
|
|
|
2021-02-18 |
2021-02-16 |
VP
Vente planifiée
|
Wagner Klaus W.
Chief Medical Officer
Dirigeant
|
156 474
-40.0%
24,32
3 805 448 USD
|
156 474
-40.0%
|
24,32
|
3 805 448 USD
|
|
|
2021-02-18 |
2021-02-16 |
VP
Vente planifiée
|
Eckelman Brendan P.
Chief Scientific Officer
Administrateur exécutif
|
17 000
-0.7%
25,90
440 300 USD
|
17 000
-0.7%
|
25,90
|
440 300 USD
|
|
|
2020-08-28 |
2020-08-26 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
100 000
+7.5%
18,99
1 898 700 USD
|
100 000
+7.5%
|
18,99
|
1 898 700 USD
|
|
|
2020-08-28 |
2020-08-26 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
80 219
+6.4%
18,84
1 511 166 USD
|
80 219
+6.4%
|
18,84
|
1 511 166 USD
|
|
|
2020-08-25 |
2020-08-25 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
70 479
+6.0%
19,39
1 366 588 USD
|
70 479
+6.0%
|
19,39
|
1 366 588 USD
|
|
|
2020-08-25 |
2020-08-25 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
14 825
+1.3%
19,23
285 100 USD
|
14 825
+1.3%
|
19,23
|
285 100 USD
|
|
|
2020-08-25 |
2020-08-24 |
A
Achat
|
VIKING GLOBAL INVESTORS LP
Actionnaire important
|
46 161
+4.1%
19,43
897 001 USD
|
46 161
+4.1%
|
19,43
|
897 001 USD
|
|
